Trial Profile
Efficacy and tolerability of dalbavancin for the treatment of gram-positive infection: A retrospective study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Catheter infections; Gram-positive infections; Skin and soft tissue infections
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 11 May 2017 New trial record
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases